With 30-year in­dus­try chops, Pamela Con­ley launch­es a pro­tein ther­a­peu­tics biotech for au­toim­mune dis­eases

Af­ter about 17 years at Por­to­la Phar­ma­ceu­ti­cals, Pamela Con­ley was ready for her next ven­ture once help­ing tran­si­tion some of the drug­mak­er’s pro­grams in­to Alex­ion in mid-to-late 2020.

Since then, she’s been set­ting up shop at au­toim­mune-fo­cused Nu­vig Ther­a­peu­tics, which broke cov­er Wednes­day with $47 mil­lion from No­vo Hold­ings, Pla­tanus, Bris­tol My­ers Squibb, Dig­i­tal­is Ven­tures and Mis­sion Bio­Cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER